Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.
暂无分享,去创建一个
H. Beltran | S. Terry | Y. Allory | A. De la taille | V. Firlej | J. Céraline | P. Maillé | P. Soyeux | F. Vacherot | L. Kheuang | N. Nicolaiew | Habiba Baaddi
[1] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[2] M. Gerstein,et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.
[3] I. Tannock,et al. New therapies for castration-resistant prostate cancer: efficacy and safety. , 2011, European urology.
[4] Sarat Chandarlapaty,et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.
[5] Michael R Hamblin,et al. CA : A Cancer Journal for Clinicians , 2011 .
[6] S. Raab. Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set , 2011 .
[7] D. Qian,et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. , 2010, Cancer research.
[8] P. Nelson,et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.
[9] Zhaohui S. Qin,et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.
[10] M. Washington,et al. Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set , 2010, The American journal of surgical pathology.
[11] S. Culine,et al. Increased expression of class III β-tubulin in castration-resistant human prostate cancer , 2009, British Journal of Cancer.
[12] A. Levine,et al. Androgenic regulation of hedgehog signaling pathway components in prostate cancer cells , 2009, Cell cycle.
[13] R. Vessella,et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. , 2009, Cancer research.
[14] Han Liu,et al. Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. , 2008, Cancer research.
[15] D. Tindall,et al. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. , 2008, Cancer research.
[16] D. McDonnell,et al. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation , 2008, Molecular Cancer Therapeutics.
[17] J. Epstein,et al. Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases , 2008, The American journal of surgical pathology.
[18] M. Cantile,et al. Neuroendocrine Differentiation in Prostate Cancer: From Lab to Bedside , 2007, Urologia Internationalis.
[19] M. Gleave,et al. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. , 2007, Human pathology.
[20] S. Terry,et al. Protocadherin‐PC promotes androgen‐independent prostate cancer cell growth , 2006, The Prostate.
[21] S. Terry,et al. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells , 2006, Oncogene.
[22] S. Batra,et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. , 2006, Endocrine-related cancer.
[23] R. Grobholz,et al. Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma , 2006, The Prostate.
[24] D. Chopin,et al. A human- and male-specific protocadherin that acts through the wnt signaling pathway to induce neuroendocrine transdifferentiation of prostate cancer cells. , 2005, Cancer research.
[25] D. Ghosh,et al. Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.
[26] R. Matusik,et al. NE-10 Neuroendocrine Cancer Promotes the LNCaP Xenograft Growth in Castrated Mice , 2004, Cancer Research.
[27] N. Nemoto,et al. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. , 2004, European urology.
[28] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[29] W. Isaacs,et al. Androgen receptor outwits prostate cancer drugs , 2004, Nature Medicine.
[30] D. Beach,et al. Myc confers androgen-independent prostate cancer cell growth. , 2003, The Journal of clinical investigation.
[31] R. Aebersold,et al. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. , 2003, Molecular endocrinology.
[32] L. Sokoll,et al. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models , 2003, The Prostate.
[33] D. Chopin,et al. The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells , 2002, Oncogene.
[34] G. Bubley,et al. Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor* , 2002, The Journal of Biological Chemistry.
[35] Y. Akao,et al. Ceramide accumulation is independent of camptothecin-induced apoptosis in prostate cancer LNCaP cells. , 2002, Biochemical and biophysical research communications.
[36] J. Isaacs,et al. A history of prostate cancer treatment , 2002, Nature Reviews Cancer.
[37] Debashis Ghosh,et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. , 2002, JAMA.
[38] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.
[39] M. Mitchell,et al. Conservation of PCDHX in mammals; expression of human X/Y genes predominantly in brain , 2000, Mammalian Genome.
[40] J. Köllermann,et al. Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs , 2000, Virchows Archiv.
[41] A. Shabsigh,et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. , 1999, The Journal of urology.
[42] S. Schwartz,et al. A new human prostate carcinoma cell line, 22Rv1 , 1999, In Vitro Cellular & Developmental Biology - Animal.
[43] A. Bjartell,et al. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. , 1998, Urology.
[44] J. Trapman,et al. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. , 1997, Molecular endocrinology.
[45] J. Trapman,et al. The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.
[46] R W Veltri,et al. Implication of cell kinetic changes during the progression of human prostatic cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] K Remberger,et al. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. , 1995, Human pathology.
[48] P. Humphrey,et al. Phorbol ester-induced apoptosis is accompanied by NGFI-A and c-fos activation in androgen-sensitive prostate cancer cells. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[49] P. A. Sant'agnese,et al. Neuroendocrine differentiation in human prostatic carcinoma , 1992 .
[50] G. Jenster,et al. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens , 1992, Journal of Steroid Biochemistry and Molecular Biology.
[51] P. di Sant'Agnese,et al. Neuroendocrine differentiation in human prostatic carcinoma. , 1992, Human pathology.
[52] F. Schröder,et al. The human prostatic cancer cell line LNCaP and its derived sublines: An in vitro model for the study of androgen sensitivity , 1991, The Journal of Steroid Biochemistry and Molecular Biology.
[53] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[54] J. Romijn,et al. Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone‐stimulated growth and drug‐induced cytostatic and cytotoxic effects , 1988, The Prostate.
[55] G. Murphy,et al. LNCaP model of human prostatic carcinoma. , 1983, Cancer research.
[56] Lippincott Williams Wilkins,et al. The American journal of surgical pathology , 1977 .